BPC-157 · research summary

Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review.

Pharmaceuticals (Basel, Switzerland) · 2025. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Review article summarizing preclinical and limited clinical data on BPC 157
“In this review, we summarize information on the biological activities of BPC 157, with particular reference to its mechanism of action and probable toxicity.”

Subjects

Preclinical animal models (rats, mice, dogs) and limited human subjects
“most of the studies presenting its consistently positive effects were performed on animal models, particularly rodents, while human studies are scarce.”

Sample size

Varies by study; specific human trial involved 42 volunteers, retrospective study involved 12 patients
“In 2015, a Phase I clinical trial conducted on 42 healthy volunteers (both sexes, aged 18–35 yrs.) was started.”

Reported findings

BPC 157 demonstrated pleiotropic beneficial effects in preclinical models including tissue injury, inflammatory bowel disease, and CNS disorders
“BPC 157, known as the “Body Protection Compound”, is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects in various preclinical models mimicking medical conditions, such as tissue injury, inflammatory bowel disease, or even CNS disorders.”
The compound has not been approved for standard medical use due to a lack of comprehensive clinical studies confirming health benefits in humans
“However, it has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans.”
BPC 157 interacts with the nitric oxide system and exhibits antioxidant activity, potentially affecting angiogenesis and neurodegenerative processes
“Most studies identify the pentadecapeptide as a compound that interacts with the nitric oxide (NO) system [23,41].”

Limitations stated by the authors

Lack of sufficient and comprehensive clinical studies in humans and unknown safety profile
“However, it has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans.”

Source: PubMed 40005999 · DOI 10.3390/ph18020185 · all study summaries

Reported findings

BPC 157 demonstrated pleiotropic beneficial effects in preclinical models including tissue injury, inflammatory bowel disease, and CNS disorders

“BPC 157, known as the “Body Protection Compound”, is a pentadecapeptide isolated from human gastric juice that demonstrated its pleiotropic beneficial effects in various preclinical models mimicking medical conditions, such as tissue injury, inflammatory bowel disease, or even CNS disorders.”

The compound has not been approved for standard medical use due to a lack of comprehensive clinical studies confirming health benefits in humans

“However, it has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans.”

BPC 157 interacts with the nitric oxide system and exhibits antioxidant activity, potentially affecting angiogenesis and neurodegenerative processes

“Most studies identify the pentadecapeptide as a compound that interacts with the nitric oxide (NO) system [23,41].”

Limitations stated by the authors

Lack of sufficient and comprehensive clinical studies in humans and unknown safety profile

“However, it has not been approved for use in standard medicine by the FDA and other global regulatory authorities due to the absence of sufficient and comprehensive clinical studies confirming its health benefits in humans.”